Long-Term Treatment Effect With Tildrakizumab in Participants With Plaque Psoriasis

Summary

The purpose of this study is to evaluate the psoriasis disease control over time in participants who had received Tildrakizumab for at least the last 5 years and have discontinued it and to describe blood and skin inflammatory biomarkers and its correlation disease relapse.

Timeline

Start

2020-01-29

Primary completion

2020-07-31

Completion

2020-07-31

Drugs

Indications